痘苗生长因子和胸苷激酶双基因缺失表达双荧光溶瘤痘病毒的构建及其对胰腺癌细胞的杀伤作用

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1026 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要
［摘要］目的: 构建痘苗生长因子(vaccinia growth factor，VGF)和胸苷激酶(thymidine kinase，TK)双基因缺失同时表达绿色荧光蛋白（GFP）和DsRed双荧光的溶瘤痘病毒，并研究其对胰腺癌细胞的杀伤作用。方法: 在病毒TK基因处利用同源重组方法将病毒晚期启动子F17R调控的GFP基因和早晚期启动子SEL调控的DsRed基因克隆入缺失VGF基因的VSC20亲本病毒，构建同时缺失VGF和TK双基因的重组溶瘤痘病毒vvDD-GFPDsRed。同时利用CCK8法和结晶紫染色法检测该病毒对胰腺癌细胞Patu8988和BxPC-3的杀伤作用。结果：通过同源重组和软琼脂筛选获得vvDD-GFP-DsRed重组溶瘤痘病毒。CCK8法结果显示，与MOI=0相比，MOI分别为1，10时，vvDD-GFP-DsRed对Patu8988细胞和BxPC-3细胞具有明显的杀伤作用，且在此范围内随MOI值增加杀伤效果逐渐增强(P均＜0.05)。与MOI=0相比，Patu8988细胞在MOI为0.01时存活率低(P＜0.05)，且在结晶紫染色法测定中形成了明显的空斑。结论：成功构建vvDDGFPDsRed重组溶瘤痘病毒，其对胰腺癌细胞具有明显的杀伤作用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：溶瘤痘病毒, 胰腺癌, 免疫治疗

Abstract：[Abstract]Objective: To construct double fluorescent oncolytic vaccinia virus expressing both GFP and DsRed with the dual deletion of vaccinia growth factor(VGF) and thymidine kinase(TK), and to explore the effect of virus on the cell lysis of pancreatic cancer cells in vitro. Methods: GFP regulated by the viral late promoter and DsRed controlled by early and late promoter SEL were inserted into viral TK locus by homologous recombination with parental viral VSC20, which was deleted by VGF gene. The anticancer effect of vvDDGFPDsRed was tested by CCK8 and crystal violet staining in vitro. Results: Recombinant vvDDGFPDsRed was got by homologous recombination and purified by soft agarose. CCK8 detection results showed that compared with MOI=0, when MOI=1,10 respectively, vvDDGFPDsRed had stronger lytic effect on Patu8988 and BxPC3 cells, and the lytic effect gradually increased among the range with MOI value increasing(P＜0.05). Compared with MOI=0, the survival rate of Patu8988 cells was lower when MOI=0.01(P＜0.05); and in the crystal violet staining method the plaque could obviously be seen. Conclusion: vvDDGFPDsRed recombinant oncolytic poxvirus was successfully constructed, which is able to kill pancreatic cancer cells in vitro.

收稿日期: 2015-12-24

基金资助:

江苏省自然科学基金资助项目(BK20151347)；上海市肿瘤研究所重点实验室开放课题(90-15-04)

通讯作者: 张尤历(通讯作者)，博士，教授，E-mail：zjyouli1957@163.com

作者简介: 徐岷(1974—)，男，博士，副教授，主要从事胰腺癌疾病的研究；

引用本文:

徐岷1，夏瑜1，周冲2，刘黎琼3，周改1，施海峰2，于峰2，4，张尤历1. 痘苗生长因子和胸苷激酶双基因缺失表达双荧光溶瘤痘病毒的构建及其对胰腺癌细胞的杀伤作用[J]. 江苏大学学报:医学版, 2016, 26(02): 143-146,153. XU Min1， XIA Yu1, ZHOU Chong2, LIU Li-qiong3, ZHOU Gai1, SHI Hai-feng2, YU Feng2,4, ZHANG You-li1. Construction of VGF and TK gene deletion expressing double fluorescent oncolytic poxviruses and its killing effect on pancreatic cancer cells. Journal of Jiangsu University(Medicine Edition), 2016, 26(02): 143-146,153.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2016/V26/I02/143

\[1\]Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress\[J\]. Nat Clin Pract Oncol, 2007, 4(2): 101-117.
\[2\]Roenigk HH Jr, Deodhar S, St Jacques R, et al. Immunotherapy of malignant melanoma with vaccinia virus \[J\]. Arch Dermatol, 1974, 109(5): 668-673.
\[3\]Puhlmann M, Brown C, Gnant M, et al. Vaccinia as a vector for tumordirected gene therapy: biodistribution of a thymidine kinasedeleted mutant\[J\]. Cancer Gene Ther, 2000, 7(1): 66-73.
\[4\]Park SH, Breitbach CJ, Lee J, et al. Phase 1b trial of biweekly intravenous pexavec(JX594), an oncolyticand immunotherapeutic vaccinia virus in colorectal cancer\[J\]. Mol Ther, 2015, 23(9): 1532-1540.
\[5\]Breitbach CJ, Moon A, Burke J, et al. A phase 2, openlabel, randomized study of pexavec (JX594) administered by intratumoral injection in patients with unresectable primary hepatocellular carcinoma\[J\]. Methods Mol Biol, 2015, 1317：343-357.
\[6\]Liu YP, Wang J, Avanzato VA, et al. Oncolytic vaccinia virotherapy for endometrial cancer\[J\]. Gynecol Oncol, 2014, 132(3): 722-729.
\[7\]Garofalo M, Iovine B, Kuryk L, et al. Oncolytic adenovirus loaded with Lcarnosine as novel strategy to enhance the antitumor activity\[J\].Mol Cancer Ther, 2016.［Epub ahead of print］.
\[8\]Deng L, Fan J, Guo M, et al. Oncolytic and immunologic cancer therapy with GMCSFarmed vaccinia virus of Tian Tan strain Guang9\[J\]. Cancer Lett, 2016, 372(2): 251-257.
\[9\]Harrington KJ, Puzanov I, Hecht JR, et al. Clinical development of talimogene laherparepvec(TVEC): a modified herpes simplex virus type1derived oncolytic immunotherapy\[J\]. Expert Rev Anticancer Ther, 2015, 15(12): 1389-1403.
\[10\]Buller RM, Chakrabarti S, Cooper JA, et al. Deletion of the vaccinia virus growth factor gene reduces virus virulence\[J\]. J Virol, 1988, 62(3): 866-874.
\[11\]McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumorselective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes\[J\]. Cancer Res, 2001, 61(24): 8751-8757.
\[12\]McCart JA, Puhlmann M, Lee J, et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vacciniamediated tumor regression \[J\]. Gene Therapy, 2000, 7(14): 1217-1223.
\[13\]Lun X, Ruan Y, Jayanthan A, et al. Doubledeleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors\[J\]. Mol Oncol, 2013, 7(5): 944-954.
\[14\]Haddad D, Chen N, Zhang Q, et al. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers\[J\]. Ann Surg Oncol, 2012, 19 (Suppl 3):S665-674.